Proteomic diagnostics firm Biodesix and drug developer Aveo Oncology said this week that they are partnering to co-develop and commercialize Aveo's non-small cell lung cancer antibody drug ficlatuzumab and Biodesix's Veristrat as a companion test to predict best responders.
NEW YORK (GenomeWeb News) – Aveo Oncology and Biodesix announced today an agreement to develop Aveo's investigational non-small cell lung cancer drug ficlatuzumab alongside Biodesix's VeriStrat serum protein test as a companion diagnostic.
Biodesix this week received an EU CE Mark for its Veristrat specimen collection and shipping kit, allowing the company to make Veristrat results available to physicians in the EU and other countries recognizing the CE Mark.
Quest Offering Lynch Syndrome Genetic Panel Testing in US
Quest Diagnostics has launched a new testing service for gauging patients' risk of Lynch Syndrome, or hereditary nonpolyposis colorectal cancer.